

abbvie

# AbbVie Pipeline Update

February 2, 2022

# AbbVie R&D Pipeline

## Phase 1

- ABBV-668 (RIPK1) Multiple Immunology Diseases
- ABBV-151 (GARP+TGFβ1) Solid Tumors
- ABBV-155 (BCL-xL ADC) Solid Tumors
- ABBV-400 (cMet ADC) NSCLC
- ABBV-181 (PD-1) Solid Tumors
- ABBV-621 (TRAIL) Solid/Heme Tumors
- ABBV-744 (BET) MF
- ABBV-927 (CD40) Solid Tumors
- ABBV-647\* (PTK7 ADC) NSCLC
- ABBV-011 (SEZ6 ADC) SCLC
- ABBV-637 (EGFR BCL-xL ADC) NSCLC
- Venclexta (BCL-2) ALL
- CCW702\* (CD3-PSMA) Prostate Cancer
- CLBR001/SW1019\* (sCAR-T) Heme Tumors
- GEN3009\* (CD37) Heme Tumors
- JAB-3068\* / JAB-3312\* (SHP2) Solid Tumors
- HPN-217\* (CD3-BCMA) MM
- ABBV-383 (CD3-BCMA) MM
- TTX-030\* (CD39) Solid Tumors
- ABBV-IMAB-TJC4\* (CD47) Heme/Solid Tumors
- ABBV-CLS-579\* (PTPN2) Solid Tumors
- ABBV-CLS-484\* (PTPN2) Solid Tumors
- ABBV-514 (CCR8) Solid Tumors
- ABBV-0805\* (α-Synuclein) PD
- AL003\* (CD33) AD
- ABBV-CLS-7262\* (eIF2B) Multiple Neuro
- AGN-241622 (Alpha2) Presbyopia
- ABBV-1882 (anti-PD1/anti-a4b7) HIV

## Phase 2

- ABBV-154 (TNF-Steroid ADC) RA
- ABBV-154 (TNF-Steroid ADC) PMR
- ABBV-154 (TNF-Steroid ADC) CD
- ABBV-599 (BTK/JAK) SLE
- ABBV-157 (RORγT) PsO
- Rinvoq (JAK 1) Vitiligo
- Acacizolcept ALPN-101\* (ICOS/CD28) SLE
- Lutikizumab (IL-1α/1β) HS
- Epcoritamab\* (CD3-CD20): R/R FL
- ABBV-CX-2029\* (CD71) Solid/Heme Tumors
- Elezanumab (RGMa) Stroke
- Elezanumab (RGMa) SCI
- AL002\* (TREM2) AD
- BoNTE (SNARE) Glabellar Lines
- OnabotA X (SNARE) Glabellar Lines
- OnabotA X (SNARE) Forehead Lines
- AGN-231868 (Chemokine) Dry Eye
- AGN-242428 (RORγ) Dry Eye
- RGX-314\* (NAV AAV8 Anti-VEGF Fab) wAMD Suprachoroidal Delivery
- RGX-314\* (NAV AAV8 Anti-VEGF Fab) DR Suprachoroidal Delivery
- AGN-193408 (Prostamide 408 SR) Glaucoma
- CF Triple Combo (CFTR-C1/CFTR-C2/CFTR-P)
- Armour Thyroid (T3T4) Hypothyroidism
- AGN-151607 (SNARE) Atrial Fibrillation

## Registrational / Phase 3

- Rinvoq (JAK 1) CD
- Rinvoq (JAK 1) GCA
- Skyrizi\* (IL-23) UC
- Imbruvica\* (BTK) 1L FL
- Imbruvica\* (BTK) 1L MCL
- Imbruvica\* (BTK) + Venclexta\* (BCL-2) R/R MCL
- Imbruvica\* (BTK) R/R FL/MZL
- Imbruvica\* (BTK) + Venclexta\* (BCL-2) 1L CLL
- Venclexta\* (BCL-2) AML Maintenance
- Venclexta\* (BCL-2) R/R MM t(11;14)
- Venclexta\* (BCL-2): MDS
- Navitoclax (BCL-2/BCL-xL) Myelofibrosis
- Epcoritamab\* (CD3-CD20): R/R DLBCL
- Teliso-V\* (cMet ADC) NSCLC
- Veliparib (PARP) BRCA Breast Cancer
- Veliparib (PARP) 1L Ovarian Cancer
- ABBV-951 (dopamine receptor) PD
- Vraylar\* (D2,5-HT1A, 5-HT2A) aMDD
- Qulipta (CGRP) Chronic Migraine Prev.
- Botox (SNARE) Masseter Prominence
- Botox (SNARE) Platysma Prominence
- RGX-314\* (NAV AAV8 Anti-VEGF Fab) wAMD Subretinal Delivery
- Aztreonam/Avibactam\* (PBP3) Infection

## Submitted

- Rinvoq (JAK 1) AS (US)
- Rinvoq (JAK 1) UC
- Rinvoq (JAK 1) nr-Axial SpA
- Skyrizi\* (IL-23) CD

- Immunology
- Oncology
- Neuroscience
- Aesthetics
- Eye Care
- Targeted Investment

As of February 2, 2022

Excludes devices in development

\*Partnered assets; See appendix for partnership summary

# Anticipated Key Pipeline Events

	2022	2023		
<b>Regulatory Approvals</b>	Rinvoq AD (US) Rinvoq AS (US) Rinvoq UC Rinvoq nr-Axial SpA Skyrizi CD	Skyrizi PsA (US) Imbruvica + Venclexta 1L CLL Venclexta Higher Risk MDS (AA) Vraylar aMDD	Rinvoq CD Imbruvica + Venclexta R/R MCL Imbruvica R/R FL/MZL Venclexta 3L+ MM w/ t(11;14)	Navitoclax 1L and R/R MF Epcoritamab 3L R/R DLBCL (AA) ABBV-951 Advanced PD Qulipta Chronic Migraine Prevention
<b>Regulatory Submissions</b>	Rinvoq CD Imbruvica + Venclexta 1L CLL Imbruvica + Venclexta R/R MCL Imbruvica R/R FL/MZL Venclexta Higher Risk MDS (for AA on Ph1 data) Epcoritamab 3L R/R DLBCL (for AA on Ph2 data) Vraylar Ph3 aMDD ABBV-951 Advanced PD Qulipta Chronic Migraine Prevention	Skyrizi UC Venclexta 3L+ MM w/ t(11;14) Imbruvica 1L FL Teliso-V NSCLC (submit for AA on Ph2 data) Navitoclax 1L and R/R MF BoNTE (Short-Acting Toxin) Glabellar Lines Botox Masseter Botox Platysma Botox Episodic Migraine		
<b>Ph3/Registrational Data Readouts</b>	Rinvoq Ph3 CD Induction/Maintenance Venclexta Ph3 3L+ MM t(11;14) (CANOVA) Imbruvica + Venclexta Ph3 R/R MCL (SYMPATICO) Imbruvica Ph3 R/R FL/MZL (SELENE) Venclexta Ph1/2 Higher Risk MDS Epcoritamab Ph2 3L R/R DLBCL Navitoclax Ph2 R/R MF Qulipta Ph3 Chronic Migraine Prevention	Skyrizi Ph3 UC Induction/Maintenance Rinvoq Ph3 GCA Imbruvica Ph3 1L FL Teliso-V Ph2 NSCLC Epcoritamab Ph3 3L DLBCL Navitoclax Ph3 1L MF BoNTE (Short-Acting Toxin) Ph3 Glabellar Lines Botox Ph3 Masseter Botox Ph3 Platysma Botox Ph3 Episodic Migraine		
<b>Early-Stage POC Data Readouts</b>	Cystic Fibrosis Triple Combo (C1/C2/P) Ph2 ABBV-154 (TNF-Steroid ADC) Ph2 RA ABBV-599 (JAK/BTK) Ph2 SLE ABBV-647 (PTK7 ADC) Ph1 NSCLC ABBV-011 (SEZ6 ADC) Ph1 SCLC ABBV-151 (GARP/TGFβ1) Ph1 Solid Tumors * TTX-030 (CD39) Ph1 Solid Tumors AGN-151607 (SNARE) Ph2 Atrial Fibrillation AGN-231868 (Chemokine) Ph2 Dry Eye AGN-242428 (RORγ) Ph2 Dry Eye	ABBV-154 (TNF-Steroid ADC) Ph2 CD Induction ABBV-154 (TNF-Steroid ADC) Ph2 PMR ABBV-GMAB-3009 (CD37) Ph1 Heme Tumors ABBV-CLS-579/484 (PTPN2) Ph1 Solid Tumors ABBV-155 (BCL-xL ADC) Ph1 Solid Tumors * Eftoza (Trail) Ph1 Solid/Heme Tumors * Elezanumab (RGMa) Ph2 Spinal Cord Injury Elezanumab (RGMa) Ph2 Stroke AGN-241622 (Alpha2) Presbyopia		

As of February 2, 2022

AA = Accelerated Approval

\*Early Oncology programs where monotherapy results did not warrant advancement; assets will continue to be evaluated in combination studies.

# AbbVie's Partnered Assets

- Imbruvica jointly developed with Janssen Biotech
- Venclexta jointly developed with Roche
- Skyrizi developed in cooperation with Boehringer Ingelheim
- Vraylar developed in cooperation with Gedeon Richter
- ABBV-0805 developed in cooperation with BioArctic
- CCW702 developed by Scripps in a first-in-patient trial and AbbVie holds option for additional development
- CLBR001/SWI019 developed by Calibr in a first-in-patient trial and AbbVie holds option for additional development
- AL002/AL003 developed by Alector through Phase 2 and AbbVie holds option for additional development
- TTX-030 developed by Trishula Therapeutics through Phase 1b and AbbVie has option to lead global development
- ABBV-2029 developed by CytomX Therapeutics through clinical proof of concept and AbbVie holds option for additional development
- ABBV-647 developed in cooperation with Pfizer
- Epcoritamab/GEN3009 developed in partnership with Genmab
- JAB-3068/3312 developed in partnership with Jacobio
- HPN-217 developed by Harpoon through Phase 1/2 and AbbVie holds option for additional development
- RGX-314 co-developed by REGENXBIO and AbbVie
- ABBV-IMAB-TJC4 co-developed by I-Mab and AbbVie
- ABBV-CLS-579/484/7262 co-developed by Calico and AbbVie
- Acazicolcept (ALPN-101) developed by Alpine Immune Sciences through current Phase 2 study and AbbVie holds option for additional development
- Aztreonam/Avibactam co-developed by Pfizer and AbbVie
- Teliso-V licensed from Seagen and Pierre Fabre